HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Chlorotrianisene

HCID 11289
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
569-57-3
Standard SMILES
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1
InChIKey
BFPSDSIWYFKGBC-UHFFFAOYSA-N
Molecular formula
C23H21ClO3
Average molar mass
380.9 g/mol
Monoisotopic mass
380.1179222

Overview

Chlorotrianisene can cause cancer according to state or federal government labeling requirements.

Names & identifiers

Preferred name
Chlorotrianisene
IUPAC
1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
English name
Chlorotrianisene
Molecular formula
C23H21ClO3
Molecular weight
380.86

Names & synonyms

chlorotrianisene569-57-3ChlortrianizenChlortrianisestrolChlortrianisenTACEChlorotrianisineChlorestroloChlorotrianizenChloortrianisestrolKhlortrianizenClorotrisin
Show more names
Chlorotrianisene (1 g)CSVPADA17NISBDCD156bNISBD1ADAM 17
HormoniseneClorestroloMerbentulAniseneMetaceRianilChlortrianisoestrolumChlorotrisin

Database identifiers

CAS
569-57-3
PubChem CID
11289
DTXSID
DTXSID1021299
ChEMBL
CHEMBL1200761
ChEBI
CHEBI:3641
UNII
6V5034L121
EC Number
209-318-6
Nikkaji
J6.531E

Properties

Computed structural properties

XLogP
6.4
Topological polar surface area
27.7 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
6
Heavy atoms
27
Formal charge
0
Complexity
442

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP6.4
OdorODORLESS
Color/Form · 2 items

CRYSTALS FROM METHANOL

SMALL WHITE CRYSTALS, OR AS CRYSTALLINE POWDER; EXHIBITS POLYMORPHISM

Solubility · 4 items

less than 0.1 mg/mL at 66 °F (NTP, 1992)

PRACTICALLY INSOL IN WATER; SOL IN ALCOHOL 0.28 G/100 ML; IN ETHER 3.6 G/100 ML; SOL IN GLACIAL ACETIC ACID, CARBON TETRACHLORIDE, VEGETABLE OILS

1 G SOL IN 360 ML OF METHANOL, 7 ML ACETONE, 2.5 ML BENZENE, IN ABOUT 1.5 ML CHLOROFORM; PRACTICALLY INSOL IN 2,2,4-TRIMETHYLPENTANE

1.99e-04 g/L

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 4 items

237 to 241 °F (NTP, 1992)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Regulatory InformationHazard Traits - Carcinogenicity
Other Safety InformationIMAP assessments - Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy-: Environment tier I assessment
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Health HazardsSYMPTOMS: When ingested, this compound can cause headache, nausea, vomiting, gynecomastia and sometimes vaginal bleeding.
Reactive GroupEthers
Reactivity Profile · 1 item

CHLOROTRIANISENE may react vigorously with strong oxidizing agents. Can react exothermically with reducing agents (such as alkali metals and hydrides) to release gaseous hydrogen. May react exothermically with both acids and bases. Various catalysts (such as acids) or initiators can cause very exothermic addition polymerization reactions.

Air and Water ReactionsSensitive to prolonged exposure to air and light. Insoluble in water.

Safety & protection

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Chemistry & industry

Pharmacology

ATC Code · 2 items

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein Binding50-80%
Pharmacodynamics · 1 item

Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.

Mechanism of Action · 1 item

Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.

Metabolism/Metabolites · 2 items

Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

113-114

114-116 °C

115 °C

Physical Description · 2 items

Small white crystals or white powder. Softens at 226 °F. Odorless. (NTP, 1992)

Solid

Stability/Shelf LifeSTABLE IN AIR
Other Experimental Properties · 2 items

SOFTENS AT 108 °C

ONE FORM MELTING @ ABOUT 116 °C & OTHER @ ABOUT 118 °C

Physicochemical properties

Melting point
114 · 114-116°
Boiling point
496.07 °C · 496.07°C (rough estimate)
Density
1.101 · 1.1010 (rough estimate)
refractive index
1.4585 · 1.4585 (estimate)
storage temp.
-20 °C · Inert atmosphere,Store in freezer, under -20°C
solubility
2 O; · insoluble in H2O; insoluble in EtOH; ≥16.1 mg/mL in DMSO
form
solid
color
Off-white to light yellow
biological source
rabbit
EWG's Food Scores
1 · 1
NCI Dictionary of Cancer Terms
TACE
FDA UNII
6 V5034L121 · 6V5034L121
ATC code
3 CA06 · G03CA06
Proposition 65 List
Chlorotrianisene
EPA Substance Registry System
Chlorotrianisene (569-57-3)
UNSPSC Code
12352203 · 12352203
NACRES
41 · NA.41
Symbol(GHS)
7 · GHS07,GHS08
Signal word
Danger
WGK Germany
3 · 3
RTECS
600000 · KV0600000
Storage Class
10 · 10 - Combustible liquids
Hazardous Substances Data
569 · 569-57-3(Hazardous Substances Data)
Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxicology

Interactions · 2 items

RELATED, NONESTROGENIC COMPD ETHAMOXYTRIPHETOL WAS FOUND TO BE STRIKINGLY ANTIESTROGENIC. IT INHIBITED...ESTROGEN GIVEN IN FORM OF NATURAL COMPD...CHLOROTRIANISENE.

ESTRADIOL NORMALLY CAUSES PRONOUNCED ENLARGEMENT OF PITUITARY, BUT WHEN CHLOROTRIANISENE WAS GIVEN CONCURRENTLY EFFECT WAS GREATLY REDUCED.

Human Toxicity Excerpts · 3 items

NEUROOPHTHALMIC LESIONS DURING ESTROGEN TREATMENT HAVE BEEN DESCRIBED. HYPERCALCEMIA MAY OCCUR, ESP IN MEN TAKING LARGE DOSES FOR PROSTATIC CARCINOMA. ALLERGIC REACTIONS INCL RASHES, ERYTHEMA MULTIFORME, ERYTHEMA NODOSUM, & CHOLESTATIC JAUNDICE. /ESTROGENS/

LEVEL OF ANTITHROMBIN III REMAINED AT DEPRESSED LEVEL IN WOMEN GIVEN 72 MG CHLOROTRIANISENE (TACE) ORALLY EVERY 12 HR FOR 4 DOSES. DEPRESSED LEVELS OF ANTITHROMBIN III MAY BE RISK FACTOR IN DEVELOPING THROMBOEMBOLISM.

SYNTHETIC NON-STEROIDAL ESTROGENS INCL...CHLOROTRIANISENE... ALTHOUGH LITTLE INFORMATION APPEARS TO BE AVAIL, THESE COMPD MUST HAVE VERY LOW SINGLE DOSE TOXICITY.

Non-Human Toxicity Excerpts · 1 item

Chlorotrianisene (CT) was evaluated for mutagenicity in the Salmonella/microsome preincubation assay using a standard protocol approved by the National Toxicology Program. CT was tested at doses of 0, 67, 100, 167, 333, 667, 1000, 1667, 3333, and 10,000 ug/plate in four Salmonella typhimurium strains (TA98, TA100, TA1535, and TA1537) in the presence and absence of Aroclor-induced rat or hamster liver S9. CT was negative in these tests and the highest ineffective dose level tested without formation of a precipitate in any Salmonella tester strain was 333 ug/plate.

Safety data

wgk
3
rtecs
KV0600000
Signal word
Danger
Symbol(GHS)
GHS07,GHS08
Storage Class
10 - Combustible liquids
Hazardous Substances Data
569-57-3(Hazardous Substances Data)

RATE OF O-DEMETHYLATION WAS MAXIMAL AT 0.4 MMOLAR NADPH. ALTHOUGH NADH DID NOT CATALYZE REACTION ALONE, IT HAD SYNERGISTIC EFFECT IN PRESENCE OF EQUIMOLAR AMT OF NADPH. EXTRACTS FROM INCUBATION MIXT CONTAINED 1 MAJOR (MONO-O-DEMETHYLATED) & A MINOR (BIS-O-DEMETHYLATED) METAB.

MeSH Pharmacological Classification · 2 items

Non-steroidal compounds with estrogenic activity.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Absorption, Distribution and Excretion · 4 items

Absorption following oral administration is rapid.

...LONG-ACTING...BECAUSE OF SEQUESTRATION IN ADIPOSE TISSUE &, THEREFORE, IS NOT WIDELY USED.

...SUGGESTS THAT DRUG IS CONVERTED IN LIVER TO MORE ACTIVE FORM. ... IT IS STORED IN FAT, FROM WHICH IT IS SLOWLY RELEASED TO GIVE SUSTAINED ACTION.

ESTROGENIC ACTIVITY HAS BEEN FOUND IN ADIPOSE TISSUE UP TO MONTH AFTER CESSATION OF THERAPY.

Cellular LocationsCytoplasm

Uses & manufacturing

UsesMEDICATION
Methods of ManufacturingPREPD BY REACTING TRI-P-ANISYLETHYLENE OR TRI-P-ANISYLETHANOL WITH CL IN INERT SOLVENT: BASFORD & ICI BRITISH PATENT 561,508 (1944).
Formulations/PreparationsCHLOROTRIANISENE, NF (TACE), IS LONG-ACTING ORAL PREPN... IT IS AVAIL IN 12-, 25-, & 72-MG CAPSULES & HAS ABOUT 1/8 ACTIVITY OF DIETHYLSTILBESTROL.
Applications · 3 items

UsesEstrogen.

UsesChlorotrianisene USP (TACE) is used to treat Androgen dependent carcinoma of the prostate.

General DescriptionSmall white crystals or white powder. Softens at 226°F. Odorless.

Upstream & downstream products

Upstream raw materials

4'-MethoxyacetophenoneGrignard reagentStyreneAnisoleChloroacetyl chlorideAnisic acid

Additional notes

DefinitionChEBI: Chlorotrianisene is a chloroalkene. It has a role as an estrogen receptor modulator, an antineoplastic agent and a xenoestrogen. It derives from a hydride of a stilbene.